Monday, November 30, 2020
Comcast to enforce 1.2TB data cap in entire 39-state territory in early 2021 | Ars Technica
Sunday, November 29, 2020
Artificial Intelligence for the Health Community: Don't leave Home without It
Monday, November 16, 2020
Effect of a Machine Learning–Derived Early Warning System for Intraoperative Hypotension vs Standard Care : Are we ready ?
Here are four things to know about why the project was put on hold.
1. One of the main challenges the audit cites is that the Oncology Expert Advisor's focus changed multiple times. The initial project focused on leukemia; however, it later shifted to lung cancer. Rob Merkel, general manager for oncology and genomics at IBM Watson Health, told the Wall Street Journal the focus changed because the project was in an "evaluation phase" at the time.
2. Another challenge for MD Anderson arose due to EHRs. The Oncology Expert Advisor was initially trained on MD Anderson's old EHR system, which was changed during the course of the project. The IBM product no longer works with MD Anderson's EHR system, and since its data has not yet been integrated with the new system, some of its information is outdated.
3. The Oncology Expert Advisor has not been piloted at additional hospitals, even though this step was included in a contract with PricewaterhouseCoopers. MD Anderson paid PwC $23 million to create a business plan for the system. Lynda Chin, the former chair of genomic medicine at MD Anderson, told the Wall Street Journal that partner hospitals showed a "lack of engagement or interest."
4. In total, the project cost MD Anderson more than $62.1 million. This figure includes payments made to external firms for planning, project management, and development for the Oncology Expert Advisor product, along with an initial MD Anderson and IBM contract of $2.4 million and $39 million in contract renewal fees.
MD Anderson is actively looking to other software contractors to potentially replace IBM's role in the project, having sent out a request for proposals that closed last month. The request specified that previous vendors could also submit proposals, but IBM declined to tell the Wall Street Journal whether it had submitted a bid.
"When it was appropriate to do so, the project was placed on hold," an MD Anderson spokesperson told Forbes in an article published last month. "As a public institution, we decided to go out to the marketplace for competitive bids to see where the industry has progressed."
These factors were wrought with logistical challenges, such as changes in focus on diseases, (from leukemia to lung cancer) and a change in EHR at MD Anderson.
Digital Health Space attributes the failure to naivete on the part of the vendor and the clinic. This was a first attempt to merge aspects of machine learning with the treatment of complex diseases with a myriad of possible combinations of anti-cancer drugs. The field itself has undergone the revolution of using powerful cellular poisons with severe side effects to precision medicine-based upon focused tools using molecular antibodies.
Predictive methods for reducing hypotensive episodes utilizing machine learning.
This study of hypotension and its role in morbidity in anesthesia was limited by the limitations of using intraarterial blood pressure monitoring. This method of monitoring blood pressure is usually limited to high-risk surgery, which excludes it from routine procedures in healthy patients. It did provide accurate assessments and was an improvement over standard non-machine learning tools.
The HYPE Randomized Clinical Trial
Thursday, October 29, 2020
Digital transformation is hot, the success rates are not, says BCG data | ZDNet
Only 30% of digital transformation projects met or exceeded their target value, according to a report from Boston Consulting Group.
BCG based its analysis on 895 digital transformation projects.
However, BCG said that another 44% created some value, but didn't hit targets and resulted in only limited long-term change. BCG also noted that 26% created a value of less than 50% of the target and produced no sustainable change.
It used to be said if there was a problem throw enough money at the challenge and it would be solved. Today technology seems to have replaced that old adage. Anyone who has implemented that philosophy knows tech is not cheap. Few even bother to analyze if there will be a return on investment. What is your end game? Do you want to increase efficiency by increasing productivity, or decrease the number of employees?
The addition of tech involves two things. One, the initial capital investment, and two maintenance either in hardware or software upgrades. Hidden personnel costs for training are essential.
Even in normal times, digital transformations can be challenging. Slower transformations allow study, comparison, and measurable outcomes. Crises such as covid 19 add workload to an already busy system. Evidence-based change and user experience in normal times allow for better study and planning prior to any implementation. All of this occurs in covid times as background noise.
These facts reveal the minimal chance of success. In addition to those known factors, the unknown challenges such as societal disruption, distancing, and disruption of supply chain logistics compound acquisition and implementation of any technology solutions.
According to BCG, most transformation efforts start off well, but ultimately lose focus. "When trying to bring everyone along with the overall plan, it can be easy to compromise and lose focus on the transformational aspiration. This is where the trouble usually starts," said BCG in its report.
There is a bright side in that a few best practices can flip the success rate to about 80%, said BCG.
Success factors include:
Research: Digital transformation plans shift due to COVID-19
A strategy with clear goals and business outcomes with the why what and how.
Commitment from the CEO to middle management for accountability. BCG noted that middle managers are often overlooked.
Deploying high-caliber talent and freeing up resources.
Address roadblocks quickly and adapt to contexts and missions.
Monitor progress toward outcomes with clear metrics and targets around processes.
A business-led modular technology and data platform.